Firebrick Pharma (ASX:FRE) has signed a license and distribution agreement with Fiji Islands company Makans, under which Makans will immediately start to promote and sell the Nasodine nasal spray in Fiji and South Pacific, the company said in a Wednesday Australian bourse filing.
Under the deal, Makans will pay the company a manufacturing/handling fee equivalent to 20% of the cost of goods of licensed products supplied by the company and also a fee of AU$1.80 per unit of licensed products sold.
The Company expects an initial order from Makans of approximately 1,000 units of Nasodine, the filing said.
The agreement is for an initial term of one year renewable for successive one-year terms, the filing added.
Company shares were down 4% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。